Top 50 Health Care VC Funds & Investors in Switzerland (November 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
78 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Information Technology, Artificial Intelligence | $20k–$2.5M |
|
Zürcher Kantonal Bank
VC Fund
|
62 | Switzerland, Germany, Japan | Seed, Series A, Series B | Health Care, Biotechnology, Medical Device | $1M–$20M |
|
Verve Ventures
VC Fund
|
49 | Switzerland, Germany, France | Series A, Seed, Series B | Software, Health Care, Biotechnology | $1.3M–$45M |
|
SICTIC
VC Fund
|
30 | Switzerland, Germany, Tanzania | Seed, Venture - Series Unknown, Pre-Seed | Software, Artificial Intelligence, Information Technology | $264k–$11M |
|
BioMedPartners
VC Fund
|
18 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $5.3M–$75M |
|
VI Partners
VC Fund
|
16 | Switzerland, Germany, United States | Series A, Series B, Series C | Health Care, Biotechnology, Software | $3.2M–$100M |
|
Kickfund
VC Fund
|
15 | Switzerland, France, Germany | Seed, Pre-Seed, Convertible Note | Health Care, Biotechnology, Manufacturing | $110k–$5.7M |
|
Bernina BioInvest
VC Fund
|
15 | Switzerland | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.5M–$65M |
|
M Ventures
VC Fund
|
14 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Versant Ventures
VC Fund
|
14 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$107M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
13 | Germany, Switzerland, United States | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Health Care | $680k–$31M |
|
redalpine
VC Fund
|
13 | Germany, Switzerland, United Kingdom | Seed, Series A, Series B | Artificial Intelligence, Health Care, Biotechnology | $1.6M–$125M |
|
Eclosion SA
VC Fund
|
12 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
GoBeyond
VC Fund
|
10 | Switzerland, Germany, France | Venture - Series Unknown, Seed, Series A | Software, Information Technology, Health Care | $495k–$5.1M |
|
StartAngels Network
VC Fund
|
10 | Switzerland, Brazil | Seed, Series A, Series B | Health Care, Medical, Medical Device | $933k–$5.7M |
|
Schroder Adveq
VC Fund
|
10 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5M–$100M |
|
Zühlke Ventures AG
VC Fund
|
10 | Switzerland, Sweden, United States | Series A, Seed, Series B | Health Care, Medical Device, Medical | $1.1M–$11M |
|
Kinled Holding
VC Fund
|
10 | United Kingdom, United States, Switzerland | Seed, Series A, Venture - Series Unknown | Health Care, Biotechnology, Software | $594k–$40M |
|
4FOX Ventures
VC Fund
|
10 | Switzerland, United States | Series A, Seed, Series B | Medical Device, Medical, Health Care | $1.8M–$69M |
|
Founderful
VC Fund
|
9 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $810k–$24M |
|
BlueOcean Ventures
VC Fund
|
9 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
Privilège Ventures
VC Fund
|
9 | Switzerland, Italy, France | Seed, Pre-Seed, Series A | Health Care, Software, Wearables | $667k–$7M |
|
SOSV
VC Fund
|
9 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $25k–$5M |
|
Swisscom Ventures
VC Fund
|
9 | Switzerland, United States, United Kingdom | Series B, Series A, Series C | Software, SaaS, Information Technology | $2M–$80M |
|
OCCIDENT
VC Fund
|
9 | Switzerland, Germany, Finland | Series A, Seed, Series C | Health Care, Biotechnology, Medical Device | $758k–$401M |
|
Novartis Venture Fund
VC Fund
|
9 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Joyance Partners
VC Fund
|
9 | United States, Germany, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Wellness | $500k–$18M |
|
b2venture
VC Fund
|
9 | Germany, Switzerland, United States | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.3M–$52M |
|
3wVentures
VC Fund
|
8 | Switzerland, Spain, Austria | Seed, Angel, Series A | Software, Health Care, Search Engine | $50k–$8M |
|
S2S Ventures
VC Fund
|
8 | Switzerland, Germany | Pre-Seed, Seed | Health Care, Artificial Intelligence, Manufacturing | $28k–$3.4M |
|
Alpana Ventures
VC Fund
|
8 | United States, Switzerland, Germany | Seed, Series A, Series B | Software, FinTech, Health Care | $729k–$45M |
|
Polytech Ventures
VC Fund
|
8 | Switzerland, United States, Spain | Seed, Series A, Venture - Series Unknown | Software, Financial Services, FinTech | $500k–$10M |
|
Lichtsteiner Foundation
VC Fund
|
8 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
Novo Holdings
VC Fund
|
8 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
EQT Life Sciences
VC Fund
|
7 | United States, Switzerland, The Netherlands | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$165M |
|
Serpentine Ventures
VC Fund
|
7 | Switzerland, Germany, United States | Seed, Pre-Seed | Software, Information Technology, Automotive | $110k–$6.3M |
|
Fongit Seed Invest
VC Fund
|
7 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1M–$3.3M |
|
Sofinnova Partners
VC Fund
|
7 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
DAA Ventures
VC Fund
|
6 | Switzerland, France | Seed, Series A, Venture - Series Unknown | Software, Information Technology, Health Care | $1.2M–$49M |
|
FortyOne Group
VC Fund
|
6 | Switzerland, Germany | Seed, Series A, Venture - Series Unknown | Software, Information Technology, Information Services | $500k–$6.2M |
|
Aglaia BioMedical Ventures
VC Fund
|
6 | The Netherlands, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Therapeutics, Pharmaceutical | $3.7M–$23M |
|
Innosuisse
VC Fund
|
6 | Switzerland, United States, United Kingdom | Grant, Pre-Seed, Seed | Health Care, Biotechnology, Medical | $16k–$16M |
|
Nina Capital
VC Fund
|
6 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $529k–$21M |
|
Broadview Ventures
VC Fund
|
5 | United States, Switzerland, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $1M–$45M |
|
Good Seed Ventures
VC Fund
|
5 | Germany, Israel, United States | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $55k–$50M |
|
Pureos Bioventures
VC Fund
|
5 | France, Switzerland, United States | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $7.1M–$125M |
|
Startfeld
VC Fund
|
5 | Switzerland | Seed, Grant, Pre-Seed | Health Care, Wellness, Manufacturing | $313k–$2.5M |
|
ETH Zurich Foundation
VC Fund
|
5 | Switzerland | Pre-Seed, Seed, Grant | Medical, Software, 3D Printing | $149k–$5.6M |
|
Translink Capital
VC Fund
|
5 | United States, China, South Korea | Series A, Series B, Series C | Software, Artificial Intelligence, Information Technology | $4.1M–$58M |
|
EIT Health
VC Fund
|
5 | United Kingdom, Spain, Ireland | Grant, Pre-Seed, Seed | Health Care, Medical Device, Medical | $27k–$1.7M |
| Access all 1186 VC funds in Switzerland Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Information Technology, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 292
- Round size: Seed $100k–$2.5M; Grant $20k–$125k; Debt Financing $100k–$532k
- Lead/follow: 94% lead, 6% follow
Portfolio highlights
- PolaSight — PolaSight delivers a direct, label free visualization of fresh tissue through its automated PolaOne benchtop polarimetric imaging platform. The technology utilizes multi spectral polarimetry to reveal quantitative physical contrast and microstructure details beyond what conventional stained slides show. This non destructive, AI ready optical mapping process provides standardized tissue data right at the bench without requiring freezing or chemical reagents.
- Swiss Soil — Live biological sensing, adaptive decision-making, and precision inputs that cut waste, respond to real conditions, and build healthier soil.
- Biodelphis Therapeutics — Swiss biotech developing next-generation protease inhibitors using Antibody-Peptide Inhibitor Conjugates (APIC).
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 208
- Round size: Seed $1M–$6M; Series A $2.1M–$13M; Series B $1.7M–$20M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely still investing — raised $150M in 2024
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 308
- Round size: Seed $1.3M–$12M; Series A $2.1M–$18M; Series B $3.9M–$45M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $61M in 2022
Portfolio highlights
- Piomic — Non-invasive treatment with minimal staff supervision to produce a durable structural, functional and cosmetic closure of hard-to-heal wounds.
- Turn2x — TURN2X decarbonizes the industry by producing Renewable Natural Gas with a unique methanation process.
- Undecimal Bio — Undecimal Bio operates as a platform biotechnology company that develops targeted delivery mechanisms for small interfering RNA (siRNA) therapeutics. The company utilizes a proprietary platform that combines combinatorial chemistry libraries with transformer-based artificial intelligence to discover molecular conjugates capable of guiding genetic medicines to specified cells outside of the liver. This approach aims to circumvent traditional delivery constraints to expand the reach of RNA therapeutics into a broader range of therapeutic areas and human organs.
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 301
- Round size: Seed $504k–$3.7M; Pre-Seed $264k–$2.7M; Venture - Series Unknown $1.2M–$11M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
- Prevision Medicine — Prevision Medicine AG is a oncology company that provides cancer therapy, tests living cancer cells, and deliver clinical insights.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 88
- Round size: Series A $5.3M–$31M; Series B $5.3M–$75M; Series C $5.3M–$47M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $106M in 2018
Portfolio highlights
- T-CURX — T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 114
- Round size: Series A $3.2M–$23M; Series B $3.3M–$41M; Series C $7M–$100M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $110M in 2020
Portfolio highlights
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
- Pay by Shopping (deal united) — paybyshopping.com Domain Name is available to Buy. Grab this great Domain from Daaz. Daaz has the lowest transaction fees in the industry. See our list of GTLD's,CCTLD's, New GTLD's,3N's, 6N's, 3L's, 6L's etc.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, France, Germany
Investor stats
- Total investments: 51
- Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4M; Convertible Note $110k–$118k
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $80M in 2023
Portfolio highlights
- Bewelab SA — Bewe is a mobile game designed to reduce cravings, using neuroscience to automatically retrain your brain and effortlessly reclaim your health.
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Helix Robotics — We are building the first commercial soft manipulator
Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.5M–$20M; Series A $15M–$65M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 190
- Round size: Seed $2.4M–$24M; Series A $5.8M–$56M; Series B $13M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Mueon — semiconductor-based systems for AI and hyperscale computing
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 339
- Round size: Series A $4.7M–$68M; Series B $10M–$105M; Series C $12M–$107M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $5M in 2024
Portfolio highlights
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- Gate Bioscience — Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.
- Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in various sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 851
- Round size: Seed $680k–$6.5M; Series A $3M–$31M; Venture - Series Unknown $911k–$12M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Extoll — EXTOLL, a leader in high-speed, ultra-low power SerDes and Chiplet connectivity, offers semiconductor IP with the smallest footprints and highest PPA. Serving global ASIC, SoC, and Chiplet markets, our portfolio includes tailored NoC (Network-on-Chip) and Die-to-Die solutions. EXTOLL drives innovation, enabling successful migration into the Chiplet Age.
- Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
- BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 207
- Round size: Seed $1.6M–$13M; Series A $2.8M–$33M; Series B $16M–$125M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $200M in 2024
Portfolio highlights
- calliora — Calliora develops an artificial intelligence platform designed to integrate hospital clinical documentation and coding systems to identify billing errors before invoices are sent to health insurers
- Basecamp Research — Novel proteins from nature. We sample the most extreme and exciting places on the planet to build the world's largest knowledge graph of natural biodiversity.
- Enact Intelligence — Enact Intelligence builds underlying technology for general-purpose robots, reimagining the entire robotic stack from the ground up to solve the ultimate bottleneck in robotics: dexterity. Rather than relying primarily on vision models, Enact builds proprietary actuators that measure force directly inside the joints. This creates a human-like "nervous system" and muscle feedback loop, allowing robots to efficiently learn and robustly execute highly precise, contact-rich physical tasks across industrial, retail, and manufacturing environments.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up can reasonably attract risk capital. Eclosion helps you to cross the bridge to convert your innovation into a realistic venture and to enter into its growth phase.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$3.3M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders. Its clients are individuals, family offices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 206
- Round size: Seed $495k–$5M; Series A $1.1M–$4.5M; Venture - Series Unknown $681k–$5.1M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
- Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
- Sensima Technology — Sensima Technology designs and supplies magnetic sensors for angle measurement and 3D magnetic field sensing. The company’s product portfolio includes MagAlpha, which instantaneously detects and delivers the angle value in digital format. Sensima Technology is based in Gland, Switzerland.
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Brazil
Investor stats
- Total investments: 31
- Round size: Seed $933k–$3.4M; Series A $2M–$3.3M; Series B $1.7M–$5.7M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Rflect — Rflect helps universities protect their business model in the age of AI by training the human skills machines cannot replace—reflection, resilience, collaboration—directly inside the curriculum for credit. As AI commoditizes knowledge and devalues degrees, Rflect secures degree value through measurable human development and audit-ready data foraccreditation, employability, and retention. Embedded as credit-bearing infrastructure, Rflect achieves 100% student usage, zero institutional churn, and long-term lock-in cycles.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5M–$22M; Series B $11M–$73M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet. The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery. Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Sweden, United States
Investor stats
- Total investments: 15
- Round size: Seed $1.1M–$3M; Series A $7M–$11M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Bottneuro — Bottneuro strives to set new standards in personalized neuromodulation - achieving better results and improving quality of life. Find out more!
- Indivi — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Kinled was founded in 1980 to retain the investment assets of the Aisher family. In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists. Since then, Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 144
- Round size: Seed $594k–$14M; Series A $1.7M–$40M; Venture - Series Unknown $1.6M–$13M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- TAG Therapeutics — TAG Therapeutics develops precision medicine approaches for telomere pathologies and aging-related diseases, such as Idiopathic Pulmonary Fibrosis and Short Telomere Syndromes
4FO Ventures
Show more...Investment focus
- Industry: Medical Device, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: Switzerland, United States
Investor stats
- Total investments: 23
- Round size: Seed $1.8M–$3.3M; Series A $1.8M–$11M; Series B $5.5M–$69M
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — Discover how Ecorobotix is revolutionizing precision agriculture with AI-driven field sprayers. Cut costs, boost yields, and farm smarter with precision ag technology.
- Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
Founderful is Switzerland’s leading pre-seed fund. Founderful is the first, fast, and founder-friendly, backing Switzerland's best tech entrepreneurs to become global market leaders. Founded in 2019 and is located in Zurich, Zurich.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 112
- Round size: Seed $1.5M–$14M; Pre-Seed $810k–$4.3M; Series A $3M–$24M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — raised $143M in 2024
Portfolio highlights
- UniSieve — UniSieve is a cleantech company that provides molecular separation membrane solutions for a wide range of applications. Its platform technology enables a unique combination of various molecular sieves and polymeric membranes, yielding reliable separation solutions. The company was founded in 2018 and is headquartered in Zurich, Switzerland.
- Fusionality — Fusionality is a Swiss fusion-technology company focused on measurement, control, and data systems for fusion devices.They combine expertise in fusion physics, control engineering, AI/ML, simulation, diagnostics, and real-time software.Their goal is to help fusion companies and research labs operate devices more efficiently and accelerate thedevelopment of commercial fusion energy.
- Exclaim Robotics — Autonomous mobile robots for the AI data center.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 18
- Round size: Seed $1M–$3.1M; Series A $2.3M–$20M; Series B $4M–$16M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- UGX.ai — Connect, process, and optimise industrial operations across manufacturing, OEM, and clean energy with UGX.AI.
- RockFlow — RockFlow is an investment wonderland for the young. Born to be brave, invest in the moment.
- official.fm — Officials.fm has done an incredible job at creating a community that brings together different artists and listeners in a very creative and dynamic way.
Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team
Show more...Investment focus
- Industry: Health Care, Software, Wearables
- Stage:Seed, Pre-Seed, Series A
- Geography: Switzerland, Italy, France
Investor stats
- Total investments: 24
- Round size: Seed $1M–$5.9M; Pre-Seed $667k–$1.6M; Series A $4.1M–$7M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $21M in 2022
Portfolio highlights
- Xsensio — Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
- ENANTIOS — ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities.
- Develop Players — Supporto clinico per ADHD e DSA online. Aiutiamo adulti, bambini e ragazzi con screening, potenziamento e percorsi psicologici personalizzati.
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3821
- Round size: Seed $125k–$5M; Pre-Seed $25k–$1.5M; Convertible Note $50k–$3.6M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
- Samphire Neuroscience — Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007. Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technical expertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services. Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A, Series C
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 159
- Round size: Series A $2M–$22M; Series B $2M–$60M; Series C $8.6M–$80M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Apono — Apono makes permission management to applications, infrastructure, and data repositories simple, secure and compliant.
- CDDS — The CDDS interceptor is an autonomous, kinetic counter drone designed to neutralize Group 1 and Group 2 Unmanned Aerial System (UAS) threats with speed and precision.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today. As an owner-managed venture capital investor with offices in Munich and Zug, OCCIDENT supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards, accompanies their portolio companies over the long term both financially as well as with their extensive experience, and thus enables founding teams to achieve outstanding results. With a strong entrepreneurial mindset, OCCIDENT invests its own money and makes decisions based on sustainable potential for success. Co-operation with the founding teams of their portfolio companies motivates the OCCIDEN team and inspires them every day. They are energized by their passion and drive, and the often very intense exchange spurs them on to tackle challenges together. OCCIDENT’s aim with each and every one of their investments is to make a positve contribution to society in a sustainable way.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series C
- Geography: Switzerland, Germany, Finland
Investor stats
- Total investments: 41
- Round size: Seed $758k–$4.6M; Series A $2.2M–$12M; Series C $8.3M–$401M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 247
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Harnessing fibrosis, unleashing life
Joyance Partners invests in companies that, through science and tech, cultivate joy to improve how we live, focusing on the health and consumer sectors from Pre-Seed to Series A.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Wellness
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 122
- Round size: Seed $960k–$6M; Pre-Seed $500k–$2M; Series A $3.6M–$18M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Siena AI — The autonomous customer service platform designed for commerce. Combine the best of human empathy and intelligent automation to transform the way your customer service teams operate and engage with shoppers.
- KilgourMD — Dermatologist-developed, the best hair growth products for thinning hair. Reduce hair fall by 30% in two months, and stimulate hair follicle growth by 200%. No known side effects.
- Nous — Find out exactly how your household finances will be affected by the cost-of-living crisis with Nous on your side.
b2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 285
- Round size: Seed $1.3M–$8.8M; Series A $3.4M–$23M; Series B $6.9M–$52M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely actively investing — fresh fund, raised $179M in 2026
Portfolio highlights
- 1Komma5° — 1KOMMA5° is a global decarbonisation energy company focusing on intelligent energy solutions and promoting a CO2-neutral lifestyle. They are a ClimateTech startup focused on CO2-neutral energy, heating, and mobility. The company functions at approximately 80 sites across 7 global markets, providing a comprehensive range of smart, integrated energysolutions including photovoltaics, energy storage, heat pumps, and electric vehicle charging stations.
- Flyboard — Human-level AI voice agents at a fraction of the cost. Transform your customer engagement with intelligent automation.
- Procuros — More and more sales teams struggle with supplier portals. We help you integrate digitally with common supplier portals and consolidate all order documents.
3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more...Investment focus
- Industry: Software, Health Care, Search Engine
- Stage:Seed, Angel, Series A
- Geography: Switzerland, Spain, Austria
Investor stats
- Total investments: 43
- Round size: Seed $50k–$3.5M; Angel $583k–$2.1M; Series A $1.1M–$8M
- Lead/follow: 2% lead, 98% follow
- Last fund: May invest from a new fund soon — raised $100M in 1999
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU Solutions — Discover how community-powered advice can turn your PDPs into trusted, high-converting content and get cited in AI search.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
S2S Ventures is a fully student-led VC fund from Switzerland, backed by some of the country's most successful entrepreneurs.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Manufacturing
- Stage:Pre-Seed, Seed
- Geography: Switzerland, Germany
Investor stats
- Total investments: 28
- Round size: Seed $954k–$3.4M; Pre-Seed $28k–$2.7M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $11M in 2021
Portfolio highlights
- Haicker — Continuous, automated vulnerability scanning for your web codebases. Cheaper, faster, and more efficient than traditional pentesters.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Forgis — Forgis is leading the next industrial revolution by introducing industrial intelligence into factories, which boosts the competitiveness of Western manufacturing.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more...Investment focus
- Industry: Software, FinTech, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, Switzerland, Germany
Investor stats
- Total investments: 103
- Round size: Seed $729k–$4M; Series A $2.1M–$14M; Series B $3M–$45M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Sinay — Sinay provides numerous solutions for maritime sector stakeholders, such as collecting and analysing maritime data.
- Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
- Tinamu — Trusted inventory intelligence delivered in real-time
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Software, Financial Services, FinTech
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 53
- Round size: Seed $500k–$3.5M; Series A $2.1M–$10M; Venture - Series Unknown $1.3M–$5.4M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth is a Swiss company building a wearable that continuously listens to your gut, turning bowel sounds and body signals into a daily picture of your gut health.
- Allegria Therapeutics — Allegria Therapeutics is a Swiss biotech company targeting mast cells to redefine the treatment of allergic and inflammatory diseases.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 415
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $35M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Vantia Therapeutics — Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, The Netherlands
Investor stats
- Total investments: 190
- Round size: Series A $7.3M–$78M; Series B $11M–$114M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $282M in 2023
Portfolio highlights
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Vaderis Therapeutics — Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases.
Serpentine Ventures (SERV) is the investment arm of the Swiss startup group. Serpentine refers to the meandering roads found across the Swiss Mountains. Unreachable mountain peaks become accessible by following the serpentine path.
Show more...Investment focus
- Industry: Software, Information Technology, Automotive
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 88
- Round size: Seed $1.1M–$6.3M; Pre-Seed $110k–$1.5M
- Lead/follow: 18% lead, 82% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Evulpo — Evulpo is a free learning website that provides an instructional videos, summaries, and practice units for curriculum-related topics. Evulpo provides assistance with all relevant curriculum in the primary, secondary, high school, and BMS levels.
- Correntics — Our vision is to make global supply chains future-proof. With our data-driven approach, a deep understanding of risks, we help our clients to reduce risks in their value chains. Through our expertise, we support our clients to improve their operations and their financial resilience in the face of climate change and emerging risks while ensuring thesustainability of their business activities.
- RAAAM Memory Technologies Ltd. — RAAAM provides a unique on-chip memory technology that offers the highest-density embedded memory solution in any standard CMOS process.RAAAM develops a high-density memory technology that allows for up to 50% higher on-chip memory density with no cost, complexity, or performance-penalty.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1M–$1.4M; Series A $2.3M–$3.3M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed builds CardioKit: live ultrasound that follows the heart during radiotherapy and gates the beam, whether the heart is the target or the organ to protect.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 360
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- IMIO — Improve efficiency across the crop nutrient cycle. IMIO natural microbial products reliably increase nutrient availability and reduce tillage.
- DMC Biotechnologies — Transforming How the World Makes Chemicals
DAA Capital Partners is a Swiss-based private equity generating significant returns on technology-driven companies and real estate opportunities
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Switzerland, France
Investor stats
- Total investments: 31
- Round size: Seed $1.2M–$4.8M; Series A $4.1M–$13M; Venture - Series Unknown $1.2M–$49M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Largo.ai — We make the data-driven movie-making accessible to the market through our high level film understanding technologies. Largo has developed data-driven intelligence, which can be introduced much earlier in the life of a film project, right from script choice and development, through filming, post-production and theatrical release. Largo empowersproduction companies with data-enhanced ROI uplift and reduction of risk.
- Touch Sensity — Touch Sensity is an information technology company that specializes in the fields of IoT and sensors.
- Cognitive Design Systems — Cognitive Design Systems (CDS) is a software company enabling designers and engineers to automate and accelerate their design process using AI. Our software converts concept designs into manufacturable, sustainable and economically viable products using machine learning algorithms.
At Fortyone AG they hold participations in non-listed companies. They are guided by the question: "Can they make a difference?". As active investors, they make investments in which, in addition to the financial resources, they can add value to their knowledge, their experience and their relationships. In order to live up to this smartmoney approach and to be able to actively influence the corporate design, they usually require the involvement of the Board of Directors. The scope of the participation depends on the requirements.
Show more...Investment focus
- Industry: Software, Information Technology, Information Services
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Switzerland, Germany
Investor stats
- Total investments: 25
- Round size: Seed $500k–$5M; Series A $2.5M–$6.2M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Meteomatics — Meteomatics is a company that specializes in the specific IT needs of the weather, energy and trading industries. With more than 10 years of experience in the development of market leading forecasting systems and the rapid processing of weather data, they are happy to assist you with tailor-made solutions.
- Catchfree — Catchfree uses a proprietary process to produce seafood substitutes that are appealing to consumers due to their excellent flavor, texture, appearance, and nutritious content.
- memox. — Memox Innovations provides workshops, scheduling, and meeting spaces. Memox Innovations was founded in 2016 and is based in Zürich, Zürich.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Pharmaceutical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Switzerland
Investor stats
- Total investments: 14
- Round size: Seed $3.7M–$3.7M; Series A $5.5M–$17M; Series B $21M–$23M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $65M in 2014
Portfolio highlights
- Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
- InteRNA Technologies — A Dutch clinical-stage biotech company InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery
- Sapreme Technologies — Enabling endosomal escape
Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 238
- Round size: Seed $500k–$16M; Grant $41k–$2.5M; Pre-Seed $16k–$4.3M
- Lead/follow: 79% lead, 21% follow
Portfolio highlights
- Actival — Actival is driven by innovation and the integration of AI tools in dentistry. It is committed to precision and oral health.
- Precise Health — Why replace antibiotics when we can make them work better? AI reads the bacterial genome, matches the adjunct. Phages first.
- Release Therapeutics — A best in class, patented, platform technology for the local and targeted delivery of highly potent therapeutic proteins to the CNS and beyond. Release Therapeutics - Treating genetic disorders without gene therapies.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 96
- Round size: Seed $2M–$6.3M; Pre-Seed $529k–$2.4M; Series A $5M–$21M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $52M in 2025
Portfolio highlights
- Biobase — Biobase is the agentic system for clinical data, connecting health systems and life science teams to turn siloed clinical data into research-ready data.
- Ladder Health — Expert speech, occupational, physical, and feeding therapy for children, right from home, with flexible virtual visits and a plan that fits real life.
- Woodway Assurance — Woodway Assurance provides EviData, an AI-driven software for automated privacy assurance on de-identified and synthetic datasets.
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures. The Foundation Leducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support. With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 86
- Round size: Seed $1M–$18M; Series A $1M–$20M; Series B $2.5M–$45M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Adient Medical — Medical Devices that Automatically Vanish - Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Viridian Therapeutics (Formerly MiRagen Therapeutics) — Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions
Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Israel, United States
Investor stats
- Total investments: 39
- Round size: Seed $55k–$7M; Series A $7.5M–$50M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
- Libre Foods — MEAT, BUT MAKE IT MUSHROOMS. GET READY TO TASTE THE POWER OF FUNGI
- Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 37
- Round size: Series A $12M–$123M; Series B $7.1M–$100M; Series C $22M–$125M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $205M in 2020
Portfolio highlights
- AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
- NovaGo Therapeutics — NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. A strategic partnership with Neurimmune provides access to a unique class of human-derived antibodies with exceptional therapeutic propertiesgenerated through their Reverse Translational Medicine™ (RTM™) technology platform.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Startfeld is the innovation and start-up network in the St.GallenBodenseeArea. In every phase of innovation, they support both ambitious entrepreneurs and established SME, who are open to new impulses and development.
Show more...Investment focus
- Industry: Health Care, Wellness, Manufacturing
- Stage:Seed, Grant, Pre-Seed
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $313k–$2.5M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Re-Nut — Re-Nut is a food processing company that engages in farming, production, and supply of Hazelnut based products.
- Catchfree — Catchfree uses a proprietary process to produce seafood substitutes that are appealing to consumers due to their excellent flavor, texture, appearance, and nutritious content.
- Ionic Wind Technologies — Ionic wind technologies, which use an internationally patented concept, alter the way airflow is generated. Instead of conventional rotating machinery, we move air with electric fields.
ETH Zurich Foundation is an independent, non-profit-making foundation under private law for the promotion of education and research at ETH Zurich.
Show more...Investment focus
- Industry: Medical, Software, 3D Printing
- Stage:Pre-Seed, Seed, Grant
- Geography: Switzerland
Investor stats
- Total investments: 22
- Round size: Seed $1.1M–$5.6M; Grant $149k–$175k; Pre-Seed $473k–$4.4M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Soverli — Soverli is a software layer that securely runs two operating systems at once on standard smartphones: a Sovereign OS you control, and an untouched standard Android.
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Tethys Robotics — Tethys Robotics develops AI-powered application oriented robotics system that enables professionals in carrying underwater search & recovery to inspection & surveillance.
Translink Capital is a trailblazing Silicon Valley VC with unmatched institutional connections to Asia's economic powerhouses.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Series B, Series C
- Geography: United States, China, South Korea
Investor stats
- Total investments: 235
- Round size: Series A $4.1M–$24M; Series B $5M–$42M; Series C $8M–$58M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Musicshake — Founded in March 2005, Musicshake is the world's most fun and sophisticated online music community, allowing people to CREATE, LISTEN, DISCOVER and SHARE originally-created music. Musicshake provides a platform for non-artists to select from 1.3 million original music samples to create their original music, share and connect across the globeand also provide a way to monetize.Based in Los Angeles, the Musicshake team includes veterans and experts from the music, technology and entertainment industry. They continue to innovate with the promise to deliver the best user experience to both Musicshake application and the website.
- Footprintku — Footprintku AI transforms unstructured component datasheets into structured digital assets, delivering DFM-compliant ECAD Libraries that accelerate design workflows, reduce errors, and drive manufacturing efficiency.
- UBIAI Technology — UBIAI Technology is a car network big data application service company, dedicated to the mining and application of big data in the car network, in order to accelerate the transformation of car companies to service-oriented enterprises, and drive innovation in the industries of auto insurance, used cars and auto finance. .
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: United Kingdom, Spain, Ireland
Investor stats
- Total investments: 106
- Round size: Seed $220k–$1.4M; Grant $27k–$1.6M; Pre-Seed $45k–$1.7M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- IDOVEN — Idoven has developed the world’s first AI cardiologist -Willem- that augments both a cardiologist’s and non-cardiology expert clinician’s ability to identify, triage and diagnose patients at scale through APIs. The company counts clients such as AstraZeneca, Abbott, Novartis, GE Healthcare, FIFPRO, Google, Santander and Real Madrid Foundation.Idoven is backed by top-tier investors and business angels including Insight Partners, Northzone and Wayra (Telefónica), Iker Casillas, Pau Gasol, the Accel Starters program, EIC Accelerator, Horizon 2020, ERC and EIT Health. The company has been awarded with numerous distinctions for its AI technology in Europe and the US, including the the European Seal of Excellence 3x from the European Commission, granted by Horizon 2020, European Research Council ERC 2x (RIA) Europe’s most prestigious research grant, supporting excellent researchers in carrying out ground-breaking, high-risk, high-gain, frontier research projects, EIC Accelerator, and EIT Health. Idoven was ranked #1 Spanish HealthTech company in 2020 by NEOTEC. Idoven has been Google for Startups Resident at Google Campus Madrid and part of the Google for Startups Global Alumni Program. The company has won the prize Emprendedor XXI from CaixaBank, the Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine, and has been awarded at South Summit 2021 as the Most Disruptive Startup, and Best Health and Wellbeing Startup. Selected by CB Insights as one of the top 150 global companies in Digital Health for 2022, and top 50 global companies in Digital Health for 2023. Idoven was recognized by TIME Magazine as one of the World's Top HealthTech Companies of 2025.
- Noah Labs — A breakthrough for heart failure: Noah Labs Ark is a Class IIa Medical Device Software with AI-driven detection of early cardiac decompensation through voice.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Health Care VC funding in Switzerland at a glance
Stats across 2.1k deals from 1.2k investors.
Access all 1186 VC funds in Switzerland Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care VC Funds in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1186 VC funds investing in Switzerland Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!